Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

INDUSTRY 2 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Cholangiocarcinoma 3 Urinary Bladder Neoplasms 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Rectal Neoplasms 1 Papillomavirus Infections 1 Pancreatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Neoplasms 1 Liver Neoplasms 1 Glioma 1 Glioblastoma 1 Colonic Neoplasms 1 Breast Neoplasms 1 Advanced Gastrointestinal Stromal Tumor (GIST) 1 Acrocephalosyndactylia 1

Interventions

lenvatinib 1 infigratinib 1 brivanib 1 Rogaratinib 1 Rabeprazole 1 Irinotecan 1 E-3810 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Acrocephalosyndactylia × infigratinib × Clear all

NCT04972253 2022-08-10

(BLASST)-3

Dana-Farber Cancer Institute

Phase 1 Withdrawn

Acrocephalosyndactylia, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡